Treatment and Prognosis of Anaplastic Thyroid Carcinoma: Experience from a Single Institution in China

Chuanzheng Sun1*, Qiuli Li2,3*, Zedong Hu1, Jiehua He3,4, Chao Li5, Guojun Li6, Xiaofeng Tao7,*–, Ankui Yang2,3*

1 Department of Head and Neck Surgery, the Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, People’s Republic of China; 2 Department of Head and Neck Surgery, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, People’s Republic of China; 3 State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, People’s Republic of China; 4 Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China; 5 Department of Head and Neck Surgery, The Tumor Hospital of Sichuan Province, Chengdu, Sichuan, People’s Republic of China; 6 Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America; 7 Radiology Department of Shanghai Ninth People’s Hospital Affiliated Shanghai JiaoTong University School of Medicine, Shanghai, People’s Republic of China

Abstract

Background: Anaplastic thyroid carcinoma (ATC), a highly aggressive malignancy, has a poor prognosis, and the consensus on the most effective treatment is needed.

Methods: Clinical data from all ATC patients treated in our institution over a 30-year period (between May 1980 and May 2010) were analyzed retrospectively with regard to mortality and survival rates (Kaplan–Meier). Multivariate analysis was performed using a Cox proportional hazards model.

Results: Sixty cases were analyzed. The overall 1- and 3-year survival rates were 35.0% and 22.9%, respectively. Univariate analysis showed that the best prognosis was seen in patients younger than 55 years, those without distant metastases, those with white blood cell (WBC) counts < 10.0 × 10⁹/L or blood platelet (PLT) counts < 300.0 × 10⁹/L at presentation, those who did not receive chemotherapy, and those who received radiotherapy doses ≥ 40 Gy or underwent surgery plus postoperative radiotherapy. According to multivariate analysis, the WBC count at first presentation and the type of therapeutic regimen independently influenced survival.

Conclusions: We found that the elevated peripheral PLT count may be an adverse prognostic factor of ATC patients. The prognosis for ATC is especially poor for patients with distant metastasis, a WBC count ≥ 10.0 × 10⁹/L, or a PLT count ≥ 300.0 × 10⁹/L, or age ≥ 55 years. WBC count at presentation and surgery with or without postoperative radiotherapy independently influenced the prognosis. Intensive treatment combining surgery with postoperative radiotherapy is recommended for ATC patients with stage IVA/B disease.

Introduction

Anaplastic thyroid carcinoma (ATC) accounts for 1.6%–5% of all thyroid cancers and is one of the most aggressive malignant tumors in humans. Only 20% of affected patients survive for 1 year after diagnosis, and the median survival duration is 3–9 months. Additionally, ATC is responsible for 14%–40% of thyroid carcinoma-related deaths [1–8]. ATC patients are typically elderly, with most older than 60 years, and manifests as a rapidly enlarging anterior neck mass that is accompanied by dyspnea, dysphagia, and vocal cord paralysis. Furthermore, 20%–50% of patients present with distant metastases, most often pulmonary [1–3,6,9]. Multimodal therapy can achieve better results in terms of avoiding death from local invasion and suffocation[1,10], but no firm conclusions have been reached concerning treatment regimens[7-14]. Thus, there is a need to investigate the effects of multimodal therapy, to determine prognostic factors in ATC,
and to provide practical and constructive information for clinicians. In this study, we conducted a retrospective review of a single institution’s experience with ATC over 3 decades and examined the clinical features, treatment efficacy, and prognostic factors that affected patient survival.

Materials and Methods

Clinical Data
The study was approved by the Ethic Committee of the Sun Yat-sen University Cancer Center; and written informed consent was obtained from all study subjects prior to enrollment. The selection criterion was that all consecutive patients pathologically diagnosed with ATC in Sun Yat-sen University Cancer Center between May 1980 and May 2010 were enrolled. All of the pathological slides were reviewed again before this study by a single expert pathologist. ATC diagnosis was established on the basis of histologic or cytologic features and confirmed by immunohistochemical staining when necessary to ensure the exclusion of poorly differentiated thyroid carcinoma or lymphoma. Data were extracted for all patients with a finally confirmed diagnosis of ATC, including age and sex of the patient; dates of diagnosis, start of treatment, and last follow-up; methods of diagnosis; white blood cell (WBC) count; blood platelet (PLT) count; tumor size; distant metastasis; acute symptoms (dysphonia, dysphagia, dyspnea); rapid growth of the tumor; methods of treatment; outcome and cause of death; T status, N status and stage according to the tumor-node-metastasis classification of the American Joint Committee on Cancer (AJCC) [15]. At the time of diagnosis, the tumor size and neck nodal status were determined by clinical and radiologic examinations, including computed tomography (CT), magnetic resonance imaging, and ultrasonography. To diagnose distant metastasis, the patients’ physicians used chest radiography, ultrasonography, bone scintigraphy, CT, and/or positron emission tomography/CT.

Immunohistochemical staining of erythropoietin (EPO), interleukin-6 (IL-6), IL-11, colony-stimulating factor 1 (CSF1)

The paraffin-embedded ATC tissue specimens were cut into 4 μm sections and baked at 60 °C for 2 hours. All sections were deparaffinized with xylene and rehydrated with graded ethanol to distilled water. After being treated with 3% H2O2 for 30 min to block the endogenous peroxidase, sections were submerged in EDTA antigen retrieval buffer (pH 8.0) and microwaved for antigen retrieval. Then the sections were treated with normal goat serum for 30 min to reduce the nonspecific binding and incubated with rabbit anti-EPO and mouse anti-IL-6 (Santa Cruz Biotechnology, Santa Cruz, CA,USA), rabbit anti-M-CSF (Eptomics, Abcam, USA) or rabbit anti-IL-11 (NOVUS Biologicals, novusbio, USA ) for overnight at 4 °C (dilutions of: anti-EPO 1:50, anti-IL-6 1:100, anti-M-CSF 1:200, anti-IL-11 1:250).The slides were washed with PBS (the proportion of tween-20 is 1:1000) three times and incubated with the anti-rabbit or anti-mouse secondary antibody for 30 min at 37 °C. For color reaction, diaminobenzidine (DAB, Zhongshan biological and technical company, Beijing, China) was used. For negative controls, the antibody was replaced by normal goat serum. The expression levels were determined by scoring the percentage and intensity of the positively stained tumor cells. All slides were assessed independently by a pathologist who did not know the identity of the patient and clinical outcome.

Follow-Up and Statistical Analysis
Follow-up information was collected by letter, telephone, which was conducted regularly by the Department of Follow-up, Sun Yat-sen University Cancer Center, or by face-to-face outpatient interviews. Overall survival (OS) duration was calculated from the date of the definitive diagnosis until the day of death or the last date in the medical records on which the patient was reported to be alive. All of the data were analyzed using SPSS 18.0 software (SPSS, Chicago, IL). Survival curves were generated using the Kaplan–Meier method, and the log-rank test was used for univariate analysis. For multivariate survival analysis, a Cox proportional hazards model was used, and P < 0.05 was considered statistically significant.

Results

Patient Characteristics
Over the past 30 years, 60 patients with ATC were referred to our institution (Table 1). The age at first diagnosis ranged from 27 to 80 years, with a median age of 58 years. The patients with ATC were clinically classified into four types according to the standard described by Sugitani [5]: common type (n = 47); incidental type (n = 5); anaplastic transformation at the neck lymph node(s) (n = 8); and no anaplastic transformation at a distant site. At the time of diagnosis, 44 (73.3%) patients presented with a sudden increase in the size of a thyroid mass. Upper airway obstruction caused by extrinsic compression, vocal cord paralysis, tumor invasion of the trachea, or trachea ingrowth was observed in 34 (56.7%) patients. Twenty-three (38.3%) patients presented with signs of hoarseness, 14 (23.3%) presented with dyspnea, and 6 (10.0%) presented with dysphagia. Distant metastasis occurred in 16 (26.7%) (bilateral lung metastases in 9 patients, bilateral lung and bone in 1, bone in 3, and unilateral lung in 3).

Therapeutic Regimen
The 60 patients underwent various treatment regimens. Two patients refused any surgery or chemoradiotherapy because of advanced disease stage or the presence of other medical problems. Chemotherapy alone was administered to 6 patients, and radiotherapy alone was administered to 6 patients. Surgical resection alone was performed in 12 patients. Only tracheostomy and/or biopsy weren’t regarded as surgical treatment in the present study (n = 5). Twenty-nine patients received multimodal treatments: surgery with postoperative radiotherapy (15 patients), surgery with postoperative chemoradiotherapy (8 patients), and surgery with chemotherapy (6 patients).
Surgical removal of the thyroid and cervical nodes, when possible and necessary, was generally the first step in treatment. Two operative procedures were performed: thyroidectomy alone (total, near-total, or subtotal thyroidectomy; n = 25) and thyroidectomy combined with neck dissection (radical neck dissection in 5 cases, modified neck dissection in 8 cases, and selective neck dissection in 3 cases; n = 16). Data on tumor resection margins were unavailable for one third of the patients who underwent surgery; therefore, it was difficult to determine whether these operative procedures should be classified as R0 (no residual tumor), R1 (microscopic residual tumor), or R2 (macroscopic residual tumor).

Twenty-three patients received external beam radiotherapy at doses ≥ 40 Gy (range: 44–78 Gy); 6 patients received external beam radiotherapy at doses of < 40 Gy (range: 14–38 Gy), with a 2-Gy dose administered at each session (5 per week). Twenty patients were treated with chemotherapy. The chemotherapy regimens included doxorubicin and cisplatin in 4

### Table 1. Survival analysis according to clinical features and type of therapy in patients with ATC.

| Prognostic factors               | Univariate analysis | Multivariate analysis |
|----------------------------------|---------------------|-----------------------|
|                                  | Median Survival (months) | 1-year OS (%) | 3-year OS (%) | P | HR | 95% CI | P |
| **Sex**                          |                      |                        |                |   |    |        |    |
| Men (n = 28)                     | 5                    | 32.1                   | 21.4           | 0.684 |    |        |    |
| Women (n = 32)                   | 8                    | 37.5                   | 24.3           | 0.879 | 0.469-1.646 | 0.686 |
| **Age**                          |                      |                        |                |   |    |        |    |
| < 55 years (n = 26)              | 15                   | 53.8                   | 38.5           | 0.033 |    |        |    |
| ≥ 55 years (n = 34)              | 6                    | 20.6                   | 11.0           | 1.829 | 0.984-3.397 | 0.056 |
| **Primary tumor size**           |                      |                        |                |   |    |        |    |
| < 6 cm (n = 31)                  | 8                    | 29.0                   | 15.1           | 0.396 |    |        |    |
| ≥ 6 cm (n = 29)                  | 11                   | 41.4                   | 31.0           | 1.075 | 0.566-2.044 | 0.825 |
| **Lymph node metastasis**        |                      |                        |                |   |    |        |    |
| N0 (n = 24)                      | 8                    | 37.5                   | 28.6           | 0.230 |    |        |    |
| N1 (n = 36)                      | 6                    | 33.3                   | 19.4           | 1.206 | 0.619-2.349 | 0.582 |
| **Distant metastasis**           |                      |                        |                |   |    |        |    |
| M0 (n = 44)                      | 8                    | 38.6                   | 29.1           | 0.032 |    |        |    |
| M1 (n = 16)                      | 3                    | 25.0                   | 6.3            | 0.607 | 0.129-2.845 | 0.526 |
| **Stage (AJCC, 2010)**          |                      |                        |                |   |    |        |    |
| IVA (n = 4)                      | 86                   | 100.0                  | 75.0           | 0.030 |    |        |    |
| IVB (n = 40)                     | 8                    | 32.5                   | 24.5           | 1.798 | 0.486-6.655 | 0.379 |
| IVC (n = 16)                     | 3                    | 25.0                   | 6.3            |    |    |        |    |
| **WBC count**                    |                      |                        |                |   |    |        |    |
| < 10.0 × 10⁹/L (n = 38)          | 11                   | 44.7                   | 33.8           | 0.006 |    |        |    |
| ≥ 10.0 × 10⁹/L (n = 22)          | 3                    | 18.2                   | 4.5            | 2.105 | 0.962-4.605 | 0.062 |
| **PLT count**                    |                      |                        |                |   |    |        |    |
| < 300.0 × 10⁹/L (n = 30)         | 8                    | 33.3                   | 25.9           | 0.025 |    |        |    |
| ≥ 300.0 × 10⁹/L (n = 12)         | 3                    | 16.7                   | 0.00           |    |    |        |    |
| **Surgery type**                 |                      |                        |                |   |    |        |    |
| None (n = 19)                    | 6                    | 31.6                   | 15.8           | 0.998 |    |        |    |
| Thyroidectomy alone (n = 25)     | 7                    | 32.0                   | 27.4           | 1.219 | 0.823-1.804 | 0.323 |
| Thyroidectomy plus neck dissection (n = 16) | 11             | 43.8                   | 25.0           |    |    |        |    |
| **Chemotherapy**                 |                      |                        |                |   |    |        |    |
| Yes (n = 20)                     | 6                    | 20.0                   | 10.0           | 0.046 |    |        |    |
| No (n = 40)                      | 9                    | 42.5                   | 29.5           | 1.310 | 0.689-2.488 | 0.410 |
| **Radiotherapy**                 |                      |                        |                |   |    |        |    |
| None or dose < 40 Gy (n = 37)    | 5                    | 24.3                   | 15.4           | 0.014 |    |        |    |
| Dose ≥ 40 Gy (n = 23)            | 14                   | 52.2                   | 34.8           | 1.140 | 0.506-2.566 | 0.752 |
| **Therapeutic regimen**          |                      |                        |                |   |    |        |    |
| Surgery plus postoperative radiotherapy (n = 15) | 27      | 73.3                   | 46.7           | 0.002 |    |        |    |
| Other therapy (n = 45)           | 5                    | 22.2                   | 15.0           | 0.448 | 0.190-1.058 | 0.067 |

Abbreviations: ATC, anaplastic thyroid carcinoma; OS, overall survival; HR, hazard ratio; CI, confidence interval; AJCC, American Joint Committee on Cancer; WBC, white blood cell; PLT, blood platelet.

*Because 18 patients did not receive PLT count examination at presentation, so only the other 42 cases were used to analyze the relationship between PLT count and prognosis.

do: 10.1371/journal.pone.0080011.t001

Surgical removal of the thyroid and cervical nodes, when possible and necessary, was generally the first step in treatment. Two operative procedures were performed: thyroidectomy alone (total, near-total, or subtotal thyroidectomy; n = 25) and thyroidectomy combined with neck dissection (radical neck dissection in 5 cases, modified neck dissection in 8 cases, and selective neck dissection in 3 cases; n = 16). Data on tumor resection margins were unavailable for one third of the patients who underwent surgery; therefore, it was difficult to determine whether these operative procedures should be classified as R0 (no residual tumor), R1 (microscopic residual tumor), or R2 (macroscopic residual tumor). Twenty-three patients received external beam radiotherapy at doses ≥ 40 Gy (range: 44–78 Gy); 6 patients received external beam radiotherapy at doses of < 40 Gy (range: 14–38 Gy), with a 2-Gy dose administered at each session (5 per week). Twenty patients were treated with chemotherapy. The chemotherapy regimens included doxorubicin and cisplatin in 4
cases; bleomycin, 5-fluorouracil, and cisplatin in 9 cases; and paclitaxel and cisplatin in 7 cases. The median duration of chemotherapy was 3 cycles, ranging from 2 to 4 cycles.

Follow-Up

The median follow-up was 8 months (range: 2–237 months). Three patients died during treatment: one died from grade IV bone-marrow toxicity caused by chemotherapy, one from pneumonia caused by bilateral vocal cord paralysis, and one from massive hemorrhage caused by a tumor penetrating the common carotid artery wall. Fifty-three patients died during follow-up. One patient died from a nontumor cause, 18 from distant metastasis (found after treatment in 2 patients), and 34 from locoregional disease progression. The remaining 4 living patients were followed until May 2012. Thus, no patients were lost for follow-up in this study. The OS rates at 1 and 3 years for all 60 patients were 35.0% and 22.9%, respectively. No significant difference in OS for the patients with the common type, the incidental type, or the type of anaplastic transformation at the neck was found, their median survival were 6, 7, and 8 months, respectively (P = 0.559).

Prognosis

Univariate analysis. The univariate analysis revealed that sex, primary tumor size, nodal status, and type of surgery were not significantly associated with prognosis. However, age, WBC count, PLT count, distant metastasis status, clinical tumor-node-metastasis stage, chemotherapy, radiotherapy, and therapeutic regimen significantly influenced the prognosis of patients with ATC (Table 1, Figure 1A-G). In the present study, surgery did not affect survival (Table 1), because the distant metastasis rate was lower in the group that underwent surgery (7/41, 17.1%) than in the nonsurgical group (9/19, 47.4%) (P = 0.014). However, among the 34 patients with upper airway obstruction, 5 patients who received tracheostomy had a worse prognosis (all...
with AJCC stage IVB ATC.

Seventeen patients were excluded from the analysis: 10 did not undergo surgery, 3 underwent surgery plus postoperative tracheostomy (3- and 5-year OS rates were 23.0% and 16.3%, respectively), although the difference was not significant ($\chi^2 = 0.484, P = 0.487$). Forty patients with stage IVB disease were selected to investigate the effects of postoperative radiotherapy. Seventeen patients were excluded from the analysis: 10 did not undergo surgery, 3 underwent surgery plus postoperative chemotherapy, and 4 underwent surgery plus postoperative chemoradiotherapy. The remaining 23 patients were divided into a surgery group ($n = 15$) and a surgery plus postoperative radiotherapy group ($n = 8$) (radiotherapy dose range: 40–70 Gy). The patients in the latter group had a better prognosis ($P = 0.050$) (Table 2, Figure 1H).

### Table 2. Effect of postoperative radiotherapy in 23 patients with AJCC stage IVB ATC.

| Treatment | n | Deaths(n) | tumor rate (%) | OS rates (%) | P |
|-----------|---|-----------|----------------|--------------|---|
| S         | 15| 14        | 13 (86.7)      | 20.0 10.0    | 0.050 |
| S + X     | 8 | 7         | 7 (87.5)       | 62.5 37.5    |    |

Abbreviations: AJCC, American Joint Committee on Cancer; ATC, anaplastic thyroid carcinoma; OS, overall survival; S, surgery; X, postoperative radiotherapy.

* No significant difference in the rates of residual disease before radiotherapy between group S and group S + X ($P = 0.956$).

doi: 10.1371/journal.pone.0080011.002

### Table 3. Cox proportional hazards model of all 60 patients with ATC.

| Factor              | HR* | 95% CI          | P     |
|---------------------|-----|-----------------|-------|
| WBC count           |     |                 |       |
| $< 10.0 \times 10^9$/L | 1.000 |                 |       |
| $\geq 10.0 \times 10^9$/L | 1.069 | 1.069–3.269 | 0.028 |

Therapeutic regimens

| Other therapy | 1.000 |
| S + X         | 0.392 | 0.200–0.770 | 0.006 |

Abbreviations: ATC, anaplastic thyroid carcinoma; HR, hazard ratio; CI, confidence interval; WBC, white blood cell; S, Surgery; X, postoperative radiotherapy.

* Adjusted by age, WBC count, distant metastasis, clinical tumor-node-metastasis stage, chemotherapy, radiotherapy, and therapeutic regimen.

doi: 10.1371/journal.pone.0080011.t003

died, 1 each at 2, 3, 4, 11, and 36 months after the initial diagnosis) than did those patients who did not receive tracheostomy (3- and 5-year OS rates were 23.0% and 16.3%, respectively), although the difference was not significant ($\chi^2 = 0.484, P = 0.487$).

In order to explore the correlations of expression of some growth factors with increase in WBC count and PLT count in the patients with ATC, we examined the expression of 4 genes (EPO, IL-6, IL-11, CSF1) in 22 patients who had tissue specimens available for analysis by IHC. We found that there were positive correlations between WBC count and CSF1 ($r = 0.370, P = 0.045$) as well as IL-11 ($r = 0.569, P = 0.003$); but we did not find that either CSF1 or IL-11 was significantly correlated with PLT count. Unfortunately, we did not find a significant correlation of either EPO or IL-6 expression with prognosis, WBC count, and PLT count in these 22 patients with ATC.

### Discussion

**Locoregional Treatment: Surgery and Postoperative Radiotherapy**

Because most clinically apparent ATCs are unresectable at presentation, it is difficult to evaluate the benefits of surgical resection without introducing selection bias. Consequently, the significance of surgical resection of the primary tumor remains controversial [6]. In the present study, the extent of resection did not affect survival ($\chi^2 = 0.005, P = 0.998$), which is similar to the findings of other studies [4,8,10,11]. However, most studies have found that curative resection significantly improved the survival of ATC patients [6,16–18]. Pierie et al [16] treated 44 of 67 patients surgically and reported 1- and 3-year OS rates of 92% and 83%, respectively, after the completed resections; 35% and 0%, respectively, after debulking; and 4% and 0%, respectively, after no resection.

It is also difficult to determine surgical management of upper airway obstructions [19–23]. Patients with upper airway obstruction could be considered for treatment with tracheostomy [21]. However, not all patients with upper airway obstruction benefit from tracheostomy. Höltung et al [22,23] described 69 of 170 patients with locally infiltrating ATC who required a tracheostomy; in 45% of these 69 patients, a tracheostomy was performed as a prophylactic procedure; the follow-up data showed no benefit from this additional procedure. In the present study, among 34 patients with upper airway obstruction, the 5 patients who received tracheostomy had a worse prognosis than did those patients who did not receive tracheostomy, which supports the findings of Höltung et al [22,23]. In general, managing the airways of ATC patients continues to be a major challenge for physicians [20].

When used alone to treat ATC, surgery, radiotherapy, or chemotherapy rarely affects OS rates significantly [1]. Therefore, multimodal therapy has increasingly become the treatment of choice for ATC. Because ATC is usually advanced at diagnosis and often cannot be resected completely, postoperative radiotherapy is desirable. Goutsouliak et al [12] reported that the median OS duration of 33 ATC patients who received doses $< 40$ Gy was significantly shorter than that of 24 patients who received $\geq 40$ Gy (3 versus 9 months, $P < 0.05$). Results published by Swaak-Kragten et al [24] or by Sherman et al [9] suggested the total radiation dose as an
important prognostic factor. Similarly, in this study, the patients who received conventional radiotherapy with doses ≥ 40 Gy had a better prognosis than did those who did not undergo radiotherapy or who received doses < 40 Gy; Furthermore, we found that postoperative radiotherapy significantly improved the prognosis of the patients with stage IVB disease (Table 2, Figure 1H). Chen et al [18] also noted that the addition of radiotherapy to surgery improved survival in patients with disease extending into the adjacent tissue, whereas the patients with disease confined to the thyroid capsule or who had further extension or distant metastatic disease did not benefit from this approach. In addition to postoperative radiotherapy, Segerhammar et al reported that hyperfractionated radiotherapy that was administered pre-operatively may improve the locoregional control [8].

**Adjuvant Therapy: Chemotherapy**

Because most ATC patients have advanced local disease or distant metastasis at presentation, most of them require chemotherapy. Doxorubicin alone or in combination with cisplatin is a common regimen, but the response rate with this regimen is low [6,7,25,26]. In recent years, many cytotoxic agents or regimens have been used to treat ATC; however, their effects remain disappointing [6,27,28]. The results in the present study indicate that chemotherapy did not benefit the patients without distant metastasis and may even have delayed opportunities for other treatments, which could increase survival. This result was different from the finding reported by Sironen [29]. They found that there were 44 patients with ATC (66% patients had a distant metastasis disease), and the patients who received chemotherapy (14 cases) had a significant longer median survival than that of the other patients (30 cases) who did not receive chemotherapy (8.5 versus 1.3 months, respectively) (P = 0.002). Unfortunately they did not provide details on the status of distant metastasis for the patients who received chemotherapy or not. Thus, the effect of chemotherapy on prognosis of the patients without distant metastasis is still needed for further investigation.

**Prognosis and Influencing Factors**

In our study, patients 55 years or older at presentation had worse 1- and 3-year OS rates than did those younger than 55 years (P = 0.033). Our results support the findings of Kebebew et al [13], who conducted a study using the United States National Cancer Institute’s Surveillance, Epidemiology, and End Results database. Their cohort comprised 516 patients with ATC. The authors concluded that an age younger than 60 years and the combination of surgery and radiotherapy were independent predictors of lower cause-specific mortality rates. Age was proved to be a negative prognostic factor for the patients with ATC in most studies [5,9,13,16,30,31]. We also found that patients with WBC counts ≥ 10.0 × 10^9/L had worse outcomes, which supports the findings of other studies [5,14,28]. A multivariate analysis showed that the WBC count was an independent prognostic factor, with a hazard ratio of 1.869. WBC counts are elevated in ATC in part because some ATC cells produce several growth factors and cytokines, such as colony-stimulating factor (CSF), interleukin-1α (IL-1α), IL-3, and IL-6, which lead to leukocytosis [32–34]. Using Csf1r<sup>op/op</sup> mice, which are deficient in the macrophage growth factor CSF1, a recent study [35] has demonstrated a crucial role for macrophages in regulating tumor progression. Because CSF can also stimulate PLT growth, we analyzed our patients’ PLT counts from their medical records. The PLT count was measured for 42 patients at their initial evaluations; the 30 patients with PLT counts < 300.0 × 10^9/L had better 1- and 3-year OS rates than did those with counts ≥ 300.0 × 10^9/L (Table 1, Figure 1C). To our knowledge, this is the first report of a relationship between the peripheral PLT count in ATC patients and patient outcomes. Unfortunately, eighteen patients did not receive the PLT count at presentation, and this variable was not included in the multivariate analysis. In the present study, although we found that a positive correlation between the expression of CSF1 or IL-11 and WBC count but not for PLT count, these results, which could be biased by our small patient’s number, need to be further validated in future larger study.

Because of its aggressive nature, ATC is classified as AJCC stage IV, regardless of tumor size, nodal status, or distant metastasis status [15]. In the present study, primary tumor size was not related to the prognosis of ATC patients, although other authors have reported that large tumors correlate with worse outcomes [2,5,8,14,18,36]. As in most reports [10,14,28], our study did not find lymph node metastasis (P = 0.230) to be a prognostic factor. However, the patients with distant metastasis had worse 1- and 3-year OS rates than did the patients without distant metastasis (P = 0.032), similar to the findings of other studies [5,8,13,14,18,28,29].

In the present study, we found that the patients who underwent surgery plus postoperative radiotherapy had the best prognosis of all treatment regimens (P = 0.002); this strategy was an independent prognostic factor with a hazard ratio of 0.392 (P = 0.006) in the multivariate analysis. Sugitani et al reported a larger analysis with 677 patients with ATC, who were collected from 38 registered institutions in Japan over 13 years [5]. They found that the clinical varieties of ATC could be the prognostic factors, and the incidental type was significantly better than the other ATC types. The survival for anaplastic transformation at the neck lymph node(s) was better than that for the common type, and the anaplastic change at a distant site had the worst prognosis (P < 0.01). In the present study, our results did not support such a conclusion (P = 0.559). We speculate that our results could be a chance finding as our study sample size was small. They also found that older patients (age ≥ 70 years), presence of acute symptoms, WBC count ≥10.0 × 10^9/L, large tumor, T4b tumor, distant metastasis were significant prognostic factors for poor survival, but unfortunately they did not evaluate the correlation between the PLT count and the prognosis of the patients with ATC.

We acknowledge that there are some limitations regarding the present study due to its retrospective nature. First, it was very unfortunate that 18 patients did not receive PLT counts examination at presentation which might decrease the strength of analysis. Secondly, the recruited patients underwent various treatment regimens, for example, different chemotherapy
regimens were used in different period. Thirdly, evaluation of the complete resection could not be performed because of the absence of partial resection margin data. In spite of the above limitations, we found several valuable prognostic factors of ATC patients in our study, especially, to our knowledge, this is the first report demonstrating the elevated peripheral PLT count may be an adverse prognostic factor of ATC patients.

In conclusion, we found the interesting relationship between the peripheral PLT count and survival of ATC patients for the first time. The prognosis for ATC is particularly poor for patients with distant metastasis, a WBC count ≥ 10.0 × 10^9/L, or an age ≥ 55 years. Accurate staging is crucial for appropriate treatment. For patients who have few risk factors and stage IVA/B disease, intensive treatment combining surgery with postoperative radiotherapy is recommended. To improve survival, particularly in patients with stage IVC ATC, innovative treatment strategies and multicenter prospective studies are needed.

Acknowledgements

The authors thank Delsigne Jill R and Diane Hackett for carefully reviewing this manuscript.

Author Contributions

Conceived and designed the experiments: AKY XFT CZS QLL ZDH CL GJL. Performed the experiments: CZS QLL ZDH JHH. Analyzed the data: AKY XFT CZS QLL ZDH JHH. Contributed reagents/materials/analysis tools: YAK, SCZ, LQL, HDZ, HJH, LGJ. Wrote the manuscript: AKY XFT CZS QLL ZDH JHH.

References

1. Derbel O, Limem S, Ségura-Ferlay C, Lifante JC, Carrie C et al. (2011) Results of combined treatment of anaplastic thyroid carcinoma (ATC). BMC Cancer 11: 469. doi:10.1186/1471-2407-11-469. PubMed: 21204775.

2. Perri F, Lorenzo GD, Scarpati GD, Buonerba C (2011) Anaplastic thyroid carcinoma: A comprehensive review of current and future therapeutic options. World J Clin Oncol 2: 150-157.

3. Wein RO, Weber RS (2011) Anaplastic thyroid carcinoma: palliation or treatment? Curr Opin Otolaryngol Head Neck Surg 19: 113-118. doi: 10.1097/MOOT.0b013e3283433af3d. PubMed: 21252687.

4. Foote RL, Molina JR, Kasperbauer JL, Lloyd RV, McVeer B et al. (2011) Enhanced survival in locoregionally confined anaplastic thyroid carcinoma: a single-institution experience using aggressive multimodal therapy. Thyroid 21: 25-30. doi:10.1089/thy.2010.0220. PubMed: 21162687.

5. Sugitani I, Miyauchi A, Sugino K, Okamoto T, Yoshida A et al. (2012) Prognostic factors and treatment outcomes for anaplastic thyroid carcinoma: ATC Research Consortium of Japan cohort study of 677 patients. World J Surg 36: 1247-1254. doi:10.1007/s00268-012-1437-z. PubMed: 22311136.

6. Ito K, Hanamura T, Murayama K, Okada T, Watanabe T et al. (2012) Multimodality therapeutic outcomes in anaplastic thyroid carcinoma: improved survival in subgroups of patients with localized primary tumors. Head Neck 34: 230-237. doi:10.1002/hed.21721. PubMed: 21500309.

7. Lim SM, Shin SJ, Chung WY, Park CS, Nam KH et al. (2012) Treatment outcome of patients with anaplastic thyroid cancer: a single center experience. Jpn J Med 53: 352-357. doi:10.3349/jymj.2012.53.2.352. PubMed: 22318823.

8. Segerhammar I, Larsson C, Nilsson IL, Bäckdahl M, Höög A et al. (2012) Anaplastic carcinoma of the thyroid gland: treatment and outcome over 13 years at one institution. J Surg Oncol 100: 981-986. doi:10.1002/jso.223177. PubMed: 22674491.

9. Sherman EJ, Lim SH, Ho AL, Ghosein RA, Fury MG et al. (2011) Concurrent doxorubicin and radiotherapy for anaplastic thyroid cancer: a critical re-evaluation including uniform pathologic review. Radiother Oncol 101: 425-430. doi:10.1016/j.radonc.2011.09.004. PubMed: 21981877.

10. Tashina L, Mitzner R, Durvesh S, Goldenberg D (2012) Dyspnea as a prognostic factor in anaplastic thyroid carcinoma. Eur Arch Otorhinolaryngol 269: 1251-1255. doi:10.1007/s00405-011-1762-0. PubMed: 21932123.

11. McVeer B, Hay ID, Giuffrida DF, Dvorak CE, Grant CS et al. (2001) Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery 130: 1028-1034. doi:10.1067/msy.2001.118266. PubMed: 11742333.

12. Goutsouliak V, Hay JH (2005) Anaplastic thyroid cancer in British Columbia 1985-1999: a population-based study. Clin Oncol 17: 75-78. doi:10.1016/j.clon.2004.07.013. PubMed: 15850607.

13. Kebebew E, Greenspan FS, Clark OH, Woebber KA, McMillan A (2005) Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer 103: 1330-1335. doi:10.1002/cncr.20936. PubMed: 15739211.

14. Sugitani I, Kasai N, Fujimoto Y, Yanagisawa A (2001) Prognostic factors and therapeutic strategy for anaplastic carcinoma of the thyroid. World J Surg 25: 617-622. doi:10.1007/s0026800208166. PubMed: 11369989.

15. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (2010) AJCC Cancer Staging Manual. 7th ed. New York: Springer Verlag.

16. Pierie JP, Muzikansky A, Gaz RD, Faquin WC, Ott MJ (2002) The effect of surgery and radiotherapy on outcome of anaplastic thyroid carcinoma. Ann Surg Oncol 9: 57-64. doi:10.1245/sao.2002.9.1.57. PubMed: 11833496.

17. Haigh PI, Iuarte PH, Wu HS, Treseler PA, Posner MD et al. (2001) Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival. Cancer 91: 2339-2342. doi:10.1002/1097-0142(20010615)91:12.<11369989.[DBM].>12. PubMed: 11413523.

18. Chen J, Tward JD, Shrieve DC, Hitchcock YJ (2008) Surgery and radiotherapy improves survival in patients with anaplastic thyroid carcinoma: analysis of the surveillance, epidemiology, and end results program 1983-2002. Am J Clin Oncol 31: 460-464. doi:10.1097/COC.0b013e31816af113. PubMed: 18838882.

19. Ito Y, Higashiyaama T, Hirooka M, Fukushima M, Inoue H et al. (2009) Investigation of the validity of UICC stage grouping of anaplastic carcinoma of the thyroid. Asian J Surg 32: 47-50. doi:10.1016/S1015-9584(09)60008-7. PubMed: 19438260.

20. Hölting T, Meybler H, Buhr H (1989) Problems of tracheotomy in locally invasive anaplastic thyroid carcinoma. Langenbecks Arch Chir 374: 72-76. doi:10.1007/BF01261613. PubMed: 2704285.

21. Hölting T, Meybler H, Buhr H (1990) Status of tracheotomy in treatment of the respiratory emergency in anaplastic thyroid cancer. Wien Klin Wochenschr 102: 264-266. PubMed: 2375115.

22. Swaan-KraFTen AT, de Witt JH, Schmitz PI, Bontenbal M, Levendag PC (2009) Multimodality treatment for anaplastic thyroid carcinoma: a critical re-evaluation including uniform pathologic review. Radiother Oncol 92: 100-104. doi:10.1016/S0167-8140(12)72856-0. PubMed: 19328572.

23. Pasieka JL (2003) Anaplastic thyroid cancer. Curr Opin Oncol 15: 78-83. doi:10.1097/00001622-200301000-00012. PubMed: 12490786.

24. Shimaoka K, Schoenfeld DA, DeWys WD, Creech RH, DeConti R (1985) A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 56: 2155-2160. doi:10.1002/1097-0142(19851101)56:7<2155::AID-CAN2>3.0.CO;2-X. PubMed: 3902203.

25. Sugino K, Ito K, Mimura T, Nagahama M, Fukunari N et al. (2002) The important role of operations in the management of anaplastic thyroid carcinoma. Surgery 131: 245-248. doi:10.1016/S0039-6060(01)00548-9. PubMed: 11894027.

26. Akiash J, Sugino K, Kitagawa W, Nagahama M, Kameyama K et al. (2011) Prognostic factors and treatment outcomes of 100 cases of
anaplastic thyroid carcinoma. Thyroid 21: 1183-1189. doi: 10.1089/thy.2010.0332. PubMed: 21936674.

29. Siironen P, Hagström J, Mäenpää HO, Louhimo J, Heikkilä A et al. (2010) Anaplastic and poorly differentiated thyroid carcinoma: therapeutic strategies and treatment outcome of 52 consecutive patients. Oncology 79: 400-408. doi: 10.1159/000322640. PubMed: 21455012.

30. Besic N, Hocevar M, Zgajnar J, Pogacnik A, Grazio-Frkovic S et al. (2005) Prognostic factors in anaplastic carcinoma of the thyroid—a multivariate survival analysis of 188 patients. Langenbecks Arch Surg 390: 203-208. doi: 10.1007/s00423-004-0524-5. PubMed: 15599758.

31. Yau T, Lo CY, Epstein RJ, Lam AK, Wan KY et al. (2008) Treatment outcomes in anaplastic thyroid carcinoma: survival improvement in young patients with localized disease treated by combination of surgery and radiotherapy. Ann Surg Oncol 15: 2500-2505. doi: 10.1245/s10434-008-0005-0. PubMed: 18581185.

32. Enomoto T, Sugawa H, Inoue D, Miyamoto M, Kosugi S et al. (1990) Establishment of a human undifferentiated thyroid cancer cell line producing several growth factors and cytokines. Cancer 65: 1971-1979. doi: 10.1002/1097-0142(19900501)65:9. PubMed: 2196988.

33. Nakada T, Sato H, Inoue F, Mizogori F, Nagayama K et al. (1996) The production of colony-stimulating factors by thyroid carcinoma is associated with marked neutrophilia and eosinophilia. Intern Med 35: 815-820. doi: 10.2169/internalmedicine.35.815. PubMed: 8933194.

34. Sato T, Omura M, Saito J, Hirasa W, Kakuta Y et al. (2000) Neutrophilia associated with anaplastic carcinoma of the thyroid: production of macrophage-colony-stimulating factor (M-CSF) and interleukin-6. Thyroid 10: 1113-1118. doi: 10.1089/thy.2000.10.1113. PubMed: 11201858.

35. Joyce JA, Pollard JW (2009) Microenvironmental regulation of metastasis. Nat Rev Cancer 9: 239-252. doi: 10.1038/nrc2618. PubMed: 19279573.

36. Kihara M, Miyauchi A, Yamashita A, Yokomise H (2004) Prognostic factors of anaplastic thyroid carcinoma. Surg Today 34: 394-398. doi: 10.1007/s00595-003-2737-6. PubMed: 15108075.